# Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

> **NCT00558428** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1098 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** fixed dose combination of telmisartan+amlodipine
- **DRUG:** amlodipine

## Key facts

- **NCT ID:** NCT00558428
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 1098 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00558428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00558428, "Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00558428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*